Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.

Autor: Regina Munter-Young, Adolfo Fuentes-Alburo, Nicholas DiGregorio, Kurt Neeser, Dmitry Gultyaev

Publikováno v: PLoS ONE, Vol 19, Iss 5, p e0302486 (2024)

Background and objectivesCorrect identification of estrogen receptor (ER) status in breast cancer (BC) is crucial to optimize treatment; however, standard of care, involving biopsy and immunohistochemistry (IHC), and other diagnostic tools such as 2-

Externí odkaz: https://doaj.org/article/ffe78734fd1a4b42a6f1d207a4fd13f3

Abstract OT2-01-01: Trial in Progress: Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy

Autor: Stephanie van de Ven, Feng Luo, Nicholas DiGregorio, Adolfo Fuentes-Alburo, Francois Tranquart

Publikováno v: Cancer Research. 83:OT2-01

BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy are the recommended first-line standard-of-care (SOC) treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc601d74218758451efde9f8f748922f
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-01

Abstract PS18-23: Population pharmacokinetics (Pop PK) of MYL-1401O (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer (mBC)

Autor: Joel Owen, Cornelius F. Waller, Hope S. Rugo, Abhijit Barve, Adolfo Fuentes-Alburo, Russell J. Rackley, Tazeen Idris, Subramanian Loganathan, Mark Liu

Publikováno v: Cancer Research. 81:PS18-23

Background: Mylan trastuzumab (MYL-1401O) is a biosimilar to trastuzumab (Herceptin®). A multicenter, double blind, randomized, phase III study (HERITAGE) compared the efficacy, safety, Pop PK and immunogenicity of MYL-1401O and trastuzumab in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35c60c714b9f37a60335c98444ee90fe
https://doi.org/10.1158/1538-7445.sabcs20-ps18-23

Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer

Autor: Adolfo Fuentes-Alburo, Ali McBride, Ivo Abraham, Karen MacDonald

To investigate the cost-efficiency and budget-neutral expanded access of biosimilar intravenous trastuzumab-dkst versus reference intravenous (trastuzumab-IV) and subcutaneous trastuzumab (trastuzumab-SC) (with/without pertuzumab) in metastatic breas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ccc298950e98f9f5ccd1adcb32ae0b8

Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer: clinical and biological concepts

Autor: Elsken van der Wall, Alejandro Mohar, Jose I. Mayordomo, Dolores Gallardo Rincón, Paula R. Pohlmann, Laura Suchil Bernal, Herbert M. Pinedo, Adolfo Fuentes Alburo, Jacobus J.M. van der Hoeven, Jan Buter, Tanja D. de Gruijl

Publikováno v: Pohlmann, P R, Suchil Bernal, L, Fuentes Alburo, A, Buter, J, Gallardo Rincón, D, Mohar, A, Mayordomo, J I, Van Der Hoeven, J J M, Van Der Wall, E, De Gruijl, T D & Pinedo, H M 2004, ' Prolonged neoadjuvant treatment plus GM-CSF in locally advanced breast cancer : Clinical and biological concepts ', Clinical and Translational Oncology, vol. 6, no. 3, pp. 130-139 . https://doi.org/10.1007/BF02710114

Results of standard multimodality treatment for locally advanced breast cancer (LABC) are still disappointing, due to a persistent high risk of relapse and death with longer-term follow-up. Increasing knowledge of tumour immunology provides the basis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fa49a77accfe0da39f2f5b9bf115615
https://doi.org/10.1007/bf02710114